Federico Pessina

Federico Pessina

Auto-generated profile, based on publicly available information

Federico Pessina

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
FPFederico Pessina
Federico Pessina
Pierina NavarriaPierina Navarria
Pierina Navarria
LCLuca Cozzi
Luca Cozzi
AAAnna Maria Ascolese
Anna Maria Ascolese
MSMatteo Simonelli
Matteo Simonelli
LBLorenzo Bello
Lorenzo Bello

4 February 2014 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
LBLorenzo Bello
Lorenzo Bello
MRMarco Riva
Marco Riva
EFEnrica Fava
Enrica Fava
VFValentina Ferpozzi
Valentina Ferpozzi
ACAntonella Castellano
Antonella Castellano
GCGabriella Cerri
Gabriella Cerri
Background Resection of motor pathway gliomas requires the intraoperative recognition of essential cortical-subcortical motor structures. The degree of involvement of motor structures is variable, and increases as result of treatments patients are submitted to. Intraoperative neurophysiology offers various stimulation modalities, which efficiency is based on the ability to recognize essential sites with the highest possible resolution in most clinical conditions. Two stimulation paradigms evolved for intraoperative guidance of motor tumors removal: the 60 Hz-technique [low frequency (LF)] and the pulse-technique [high frequency-(HF)], delivered by bipolar or monopolar probe respectively. Most surgical teams rely on to either of the 2 techniques. The key point is the integration of the choice of the stimulation modality with the clinical context. Methods In 591 tumors involving the corticospinal tract, the use of HF and LF was tailored to the clinical context defined by patient clinical history and tumor features (by imaging). The effect was evaluated on the feasibility of mapping, the impact on immediate and permanent morbidity, the extent of resection, and the number of patients treated. Results By integrating the choice of the probe and the stimulation protocol with patient clinical history and tumor characteristics, the best probe-frequency match was identified for the different sets of clinical conditions. This integrative approach allows increasing the extent of resection and patient functional integrity, and greatly expands the number of patients who could benefit from surgery. Conclusions The integration of stimulation modalities with clinical context enhances the extent and safety of resection and expands the population of patients who could benefit from surgical treatment.

21 January 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Egesta LopciEgesta Lopci
Egesta Lopci
MRMarco Riva
Marco Riva
LOLaura Olivari
Laura Olivari
FRFabio Raneri
Fabio Raneri
Riccardo SoffiettiRiccardo Soffietti
Riccardo Soffietti
ACArturo Chiti
Arturo Chiti

2 June 2016 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
Pierina NavarriaPierina Navarria
Pierina Navarria
FPFederico Pessina
Federico Pessina
LCLuca Cozzi
Luca Cozzi
AAAnna Maria Ascolese
Anna Maria Ascolese
FRFiorenza De Rose
Fiorenza De Rose
MSMarta Scorsetti
Marta Scorsetti
Hypo-fractionated stereotactic radiotherapy (HSRT) is emerging as a valid treatment option for patients with single, large brain metastases (BMs). We analyzed a set of our patients treated with HSRT. The aim of this study was to evaluate local control (LC), brain distant progression (BDP), toxicity and overall survival (OS). From July 2011 to May 2015, 102 patients underwent HSRT consisting of 27Gy/3fractions for lesions 2.1–3 cm and 32Gy/4 fractions for lesions 3.1–5 cm. Local progression was defined as increase of the enhancing abnormality on MRI, and distant progression as new brain metastases outside the irradiated volume. Toxicity in terms of radio-necrosis was assessed using contrast enhanced T1MRI, T2 weighted-MRI and perfusion- MRI. The median maximum diameter of BM was 2.9 cm (range 2.1–5 cm), the median gross target volume (GTV) was 16.3 cm3 and the median planning target volume (PTV) was 33.7 cm3 The median,1,2-year local control rate was 30 months, 96, 96 %; the median, 1–2-year rate of BDP was 24 months, 12, 24 %; the median,1,2-year OS was 14 months, 69, 33 %. KPS and controlled extracranial disease were associated with significant survival benefit (p <0.01). Brain radio-necrosis occurred in six patients (5.8 %). In patients with single, large BMs unsuitable for surgical resection, HSRT is a safe and feasible treatment, with good brain local control and limited toxicity.

17 January 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FOFrancesca Orzan
Francesca Orzan
FBFrancesca De Bacco
Francesca De Bacco
ELElisabetta Lazzarini
Elisabetta Lazzarini
Giovanni CrisafulliGiovanni Crisafulli
Giovanni Crisafulli
AGAlessandra Gasparini
Alessandra Gasparini
CBCarla Boccaccio
Carla Boccaccio
Purpose: Current glioma diagnostic guidelines call for molecular profiling to stratify patients into prognostic and treatment subgroups. In case the tumor tissue is inaccessible, cerebrospinal fluid (CSF) has been proposed as a reliable tumor DNA source for liquid biopsy. We prospectively investigated the use of CSF for molecular characterization of newly diagnosed gliomas. Experimental Design: We recruited two cohorts of newly diagnosed patients with glioma, one (n = 45) providing CSF collected in proximity of the tumor, the other (n = 39) CSF collected by lumbar puncture (LP). Both cohorts provided tumor tissues by surgery concomitant with CSF sampling. DNA samples retrieved from CSF and matched tumors were systematically characterized and compared by comprehensive (NGS, next-generation sequencing) or targeted (ddPCR, droplet digital PCR) methodologies. Conventional and molecular diagnosis outcomes were compared. Results: We report that tumor DNA is abundant in CSF close to the tumor, but scanty and mostly below NGS sensitivity threshold in CSF from LP. Indeed, tumor DNA is mostly released by cells invading liquoral spaces, generating a gradient that attenuates by departing from the tumor. Nevertheless, in >60% of LP CSF samples, tumor DNA is sufficient to assess a selected panel of genetic alterations (IDH and TERT promoter mutations, EGFR amplification, CDKN2A/B deletion: ITEC protocol) and MGMT methylation that, combined with imaging, enable tissue-agnostic identification of main glioma molecular subtypes. Conclusions: This study shows potentialities and limitations of CSF liquid biopsy in achieving molecular characterization of gliomas at first clinical presentation and proposes a protocol to maximize diagnostic information retrievable from CSF DNA.

1 September 2018 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
MSMatteo Simonelli
Matteo Simonelli
PPPasquale Persico
Pasquale Persico
MPMatteo Perrino
Matteo Perrino
PZPaolo Andrea Zucali
Paolo Andrea Zucali
Pierina NavarriaPierina Navarria
Pierina Navarria
ASArmando Santoro
Armando Santoro